Cytek Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
CTKB$5.79-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
Cytek Biosciences, Inc
Consolidated Statements of Stockholders’ Equity
| Common stock · Additional paid-in capital · Accumulateddeficit · Accumulated other comprehensive income (loss) · Totalstockholders’ equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (In thousands, except share data) · Shares · Amount | |||||||||||
| Balances at December 31, 2024 | 129,205,901 | $129.00 | $430,791.00 | $(35,199.00) | $16.00 | $395,737.00 | |||||
| Shares issued in connection with employee stock plans | 500,830 | 1 | 38 | — | — | 39 | |||||
| Shares of Common Stock withheld related to net share settlement | (29,006) | — | (129) | — | — | (129) | |||||
| Repurchase of shares | (2,078,583) | (2) | (10,625) | — | — | (10,627) | |||||
| Stock-based compensation | — | — | 6,630 | — | — | 6,630 | |||||
| Unrealized loss on marketable securities | — | — | — | — | (65) | (65) | |||||
| Foreign currency translation adjustment, net of tax | — | — | — | — | (560) | (560) | |||||
| Net loss | — | — | — | (11,402) | — | (11,402) | |||||
| Balances at March 31, 2025 | 127,599,142 | $128 | $426,705 | $(46,601) | $(609) | $379,623 | |||||
| Shares issued in connection with employee stock plans | 545,702 | 1 | 65 | — | — | 66 | |||||
| Proceeds from Employee Stock Purchase Plan | 292,212 | — | 703 | — | — | 703 | |||||
| Shares of Common Stock withheld related to net share settlement | (37,938) | (1) | (102) | — | — | (103) | |||||
| Repurchase of shares | (1,214,005) | (1) | (4,509) | — | — | (4,510) | |||||
| Stock-based compensation | — | — | 6,791 | — | — | 6,791 | |||||
| Unrealized loss on marketable securities | — | — | — | — | (33) | (33) | |||||
| Foreign currency translation adjustment, net of tax | — | — | — | — | 603 | 603 | |||||
| Net loss | — | — | — | (5,583) | — | (5,583) | |||||
| Balances at June 30, 2025 | 127,185,113 | $127 | $429,652 | $(52,184) | $(38) | 377,557 | |||||
| Shares issued in connection with employee stock plans | 721,661 | 1 | 136 | — | — | 137 | |||||
| Shares of Common Stock withheld related to net share settlement | (41,944) | — | (170) | — | — | (170) | |||||
| Repurchase of shares | — | — | 29 | — | — | 29 | |||||
| Stock-based compensation | — | — | 5,638 | — | — | 5,638 | |||||
| Unrealized gain on marketable securities | — | — | — | — | 118 | 118 | |||||
| Foreign currency translation adjustment, net of tax | — | — | — | — | 741 | 741 | |||||
| Net loss | — | — | — | (5,478) | — | (5,478) | |||||
| Balances at September 30, 2025 | 127,864,830 | $128 | $435,284 | $(57,662) | $821 | $378,571 | |||||
| Common stock · Additional paid-in capital · Accumulateddeficit · Accumulated other comprehensive income (loss) · Totalstockholders’ equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (In thousands, except share data) · Shares · Amount | |||||||||||
| Balances at December 31, 2023 | 130,714,906 | $131 | $423,386 | $(29,178) | $(1,275) | $393,064 | |||||
| Shares issued in connection with employee stock plans | 559,325 | — | 506 | — | — | 506 | |||||
| Shares of Common Stock withheld related to net share settlement | (20,050) | — | (148) | — | — | (148) | |||||
| Stock-based compensation | — | — | 5,640 | — | — | 5,640 | |||||
| Unrealized loss on marketable securities | — | — | — | — | (35) | (35) | |||||
| Foreign currency translation adjustment, net of tax | — | — | — | — | (244) | (244) | |||||
| Net loss | — | — | — | (6,169) | — | (6,169) | |||||
| Balances at March 31, 2024 | 131,254,181 | $131 | $429,384 | $(35,347) | $(1,554) | $392,614 | |||||
| Shares issued in connection with employee stock plans | 506,375 | 1 | 224 | — | — | 225 | |||||
| Proceeds from Employee Stock Purchase Plan | 210,496 | — | 1,007 | — | — | 1,007 | |||||
| Shares of Common Stock withheld related to net share settlement | (21,532) | — | (130) | — | — | (130) | |||||
| Repurchase of shares | (444,319) | — | (2,670) | — | — | (2,670) | |||||
| Stock-based compensation | — | — | 7,152 | — | — | 7,152 | |||||
| Unrealized loss on marketable securities | — | — | — | — | (16) | (16) | |||||
| Foreign currency translation adjustment, net of tax | — | — | — | — | 1,375 | 1,375 | |||||
| Net loss | — | — | — | (10,434) | — | (10,434) | |||||
| Balances at June 30, 2024 | 131,505,201 | $132 | $434,967 | $(45,781) | $(195) | $389,123 | |||||
| Shares issued in connection with employee stock plans | 481,509 | — | 146 | — | — | 146 | |||||
| Shares of Common Stock withheld related to net share settlement | (26,344) | — | (146) | — | — | (146) | |||||
| Repurchase of shares | (2,194,355) | (2) | (11,948) | — | — | (11,950) | |||||
| Stock-based compensation | — | — | 7,053 | — | — | 7,053 | |||||
| Unrealized gain on marketable securities | — | — | — | — | 195 | 195 | |||||
| Foreign currency translation adjustment, net of tax | — | — | — | — | 101 | 101 | |||||
| Net income | — | — | — | 941 | — | 941 | |||||
| Balances at September 30, 2024 | 129,766,011 | $130 | $430,072 | $(44,840) | $101 | $385,463 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.